Mirion Technologies is a radiation-measurement franchise whose equity now prices a nuclear-cycle story that the income statement has only begun to convert. The company closed two nuclear-platform deals last year, then printed a June quarter in which reported sales jumped while organic growth barely moved. That gap is the entire investment debate. The market has already cut the multiple from the prior-year peak near $30, and the remaining question is whether backlog and small-modular-reactor orders turn into mid-single-digit-plus organic growth or stay as an order-book exhibit.
The June quarter delivered about $267 million of revenue. Acquisitions supplied almost all of the year-on-year lift. Organic growth barely moved, while the cash-earnings proxy management uses rose faster than sales and the margin recovered from the first-quarter squeeze. Orders including the acquired books jumped, and remaining performance obligations, the contracted work still to be delivered, sit above $1 billion. The order tape is the bull case and the conversion lag is the bear case.
Management reaffirmed full-year targets that still assume a second-half step-up: total growth in the low twenties, organic growth in the mid-single digits, and adjusted cash earnings of roughly $285 million to $300 million. Medical hardware slipped even as radiation-therapy quality-assurance work stayed firm. A cancelled Chinese new-build order from 2019 did not change the guide, but it did remind investors that long-cycle nuclear awards can vanish. Does the second half deliver the organic acceleration the reaffirmed range requires, or does the equity keep trading as a nuclear option with industrial-instrumentation cash flow?